Dr. David Sallman, MD
Claim this profileMoffitt Cancer Center
Area of expertise
Myelodysplastic Syndrome
David Sallman, MD has run 9 trials for Myelodysplastic Syndrome. Some of their research focus areas include:
Acute Myelogenous Leukemia
David Sallman, MD has run 8 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Moffitt Cancer Center
H. Lee Moffitt Cancer Center And Research Institute
Clinical Trials David Sallman, MD is currently running
SX-682 + Decitabine
for Myelodysplastic Syndrome
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
Recruiting
1 award
Phase 1
Venetoclax + CLAG-M
for AML
This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
Recruiting
1 award
Phase 2
6 criteria
More about David Sallman, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments David Sallman, MD has experience with
- Venetoclax
- Azacitidine
- Canakinumab Injection
- Darbepoetin Alfa
- SX-682
- IMGN632
Breakdown of trials David Sallman, MD has run
Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
AML
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Sallman, MD specialize in?
David Sallman, MD focuses on Myelodysplastic Syndrome and Acute Myelogenous Leukemia. In particular, much of their work with Myelodysplastic Syndrome has involved TP53 positive patients, or patients who are Hgb.
Is David Sallman, MD currently recruiting for clinical trials?
Yes, David Sallman, MD is currently recruiting for 5 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that David Sallman, MD has studied deeply?
Yes, David Sallman, MD has studied treatments such as Venetoclax, Azacitidine, Canakinumab Injection.
What is the best way to schedule an appointment with David Sallman, MD?
Apply for one of the trials that David Sallman, MD is conducting.
What is the office address of David Sallman, MD?
The office of David Sallman, MD is located at: Moffitt Cancer Center, Tampa, Florida 33612 United States. This is the address for their practice at the Moffitt Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.